AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.
Frequently asked questions
What sector does Accustem Sciences Inc (ACUT) operate in?
Accustem Sciences Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Accustem Sciences Inc (ACUT) current stock price?
As of the latest data, Accustem Sciences Inc stock price is $0.24, with a previous close of $0.24. Accustem Sciences Inc gained $0.00 in the last trading session, representing a 0.38% increase.
What is Accustem Sciences Inc (ACUT) current market capitalization?
Accustem Sciences Inc market cap is approximately 3.86 million.
What is Accustem Sciences Inc (ACUT) Earnings Per Share (EPS)?
The trailing EPS is -$0.12.
Does Accustem Sciences Inc (ACUT) pay dividends?
No. Accustem Sciences Inc does not pay a dividend.
What is Accustem Sciences Inc (ACUT) beta (volatility) score?
Accustem Sciences Inc has a beta of 1.911, suggesting it is more volatile than the market.
